Number of swine flu cases grows
ATLANTA According to the Centers for Disease Control and Prevention’s latest update on confirmed cases of H1N1 influenza infections, there are now 403 confirmed cases across 38 states. The number has grown from 286 confirmed cases across 36 states reported Monday, though CDC officials reported that the influenza outbreak appears to be toward the end of its course during morning news programs earlier today.
There continues to be only one reported death attributed to the H1N1 virus in Texas.
The confirmed cases include, by state:
Alabama 4 Arizona 17 California 49 Colorado 6 Connecticut 2 Delaware 20 Florida 5 Georgia 1 Idaho 1 Illinois 82 Indiana 3 Iowa 1 Kansas 2 Kentucky 1 Louisiana 7 Maine 1 Maryland 4 Massachusetts 6 Michigan 2 Minnesota 1 Missouri 1 Nebraska 1 Nevada 1 New Hampshire 1 New Jersey 6 New Mexico 1 New York 90 North Carolina 1 Ohio 3 Oregon 15 Pennsylvania 1 Rhode Island 1 South Carolina 16 Tennessee 2Texas 41Utah 1 Virginia 3 Wisconsin 3
CDC expects that more cases, more hospitalizations and more deaths from this outbreak will occur over the coming days and weeks, the agency continued to state.
MannKind has dip in profit, flat sales
VALENCIA, Calif. A drug company focused on developing drugs for diabetes and cancer reported a reduction in operating, research and development and general and administrative expenses of more than $32 million in its first quarter 2009 financial results Monday.
MannKind Corp. said the decrease in research and development expenses, by $15.6 million, was primarily due to decreased costs associated with the clinical development of the fast-acting insulin Afresa.
Cash, cash equivalents and marketable securities were $30.2 million as of March 31, compared with $46.5 million on Dec. 31 and $269.1 million on March 31, 2008.
“This past quarter was extremely busy for MannKind, culminating in our submission to the FDA of a new drug application for Afresa.” chairman and CEO Alfred Mann said in a statement. “With this milestone accomplished, we are now turning our attention to commercial readiness activities.”
Vagisil launches new feminine hygiene product
WHITE PLAINS, N.Y. As a brand leader in the feminine hygiene product market, Combe on Monday announced the introduction of Vagisil Satin — a fast-absorbing creme that provides quick and long-lasting relief from itch and irritation as it soothes and helps heal the skin.
“Whether at work, home or on the go, external vaginal discomfort not only causes physical stress, but also puts a damper on a woman’s mood and confidence level,” stated Adelaide Nardone, board certified OB/GYN.
According to the Journal of Urgent Care, vulvovaginitis is the cause of approximately 10 million office visits in the United States annually. Vulvovaginitis can be characterized by symptoms of itching, irritation, burning, redness, discharge and discomfort.
“These uncomfortable and sometimes painful symptoms affect women of all ages and are common gynecological concerns,” commented Jeanne Collins, Combe senior brand manager of marketing, feminine hygiene. “We are thrilled about the launch of Vagisil Satin as we continually strive to meet the needs of women by offering them a solution that immediately helps them feel more comfortable.”
Vagisil Satin contains 1% hydrocortisone acetate and provides 12 hours of relief from itch, discomfort and distraction.